An expansion planned at the UK’s Alderley Park will result in a new facility for the drug research firm Sygnature Discovery which will double their drug metabolism and pharmacokinetics (DMPK) department.
The expansion will be carried out at both Sygnature sites: Alderley Park and Nottingham, England. Within the expansion, the firm plans on carrying out a sustained recruitment programme.
Chief operating officer Dr. Jonathan Williams said “The North West has a wealth of expertise in the field of DMPK and as Alderley Park is home to the UK’s largest life science campus we wanted to align our growth with theirs”.
0 Comments